Importer of Controlled Substances Application: Nexus Pharmaceuticals, Inc., 1435 [2022-00329]
Download as PDF
<![CDATA[
1435
Federal Register / Vol. 87, No. 7 / Tuesday, January 11, 2022 / Notices
Controlled substance
Drug code
Amphetamine ...
Lisdexamphetamine.
Methylphenidate
Phenylacetone ..
Tapentadol ........
1100
1205
II
II
1724
8501
9780
II
II
II
The company plans to bulk
manufacture the above-listed controlled
substances in bulk for distribution to its
customers. No other activities for these
drug codes are authorized for this
registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2022–00325 Filed 1–10–22; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–942]
Bulk Manufacturer of Controlled
Substances Application: Johnson
Matthey, Inc.
Drug Enforcement
Administration, Justice.
AGENCY:
ACTION:
Notice of application.
Johnson Matthey, Inc., has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 14, 2022. Such persons
may also file a written request for a
hearing on the application on or before
March 14, 2022.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
khammond on DSKJM1Z7X2PROD with NOTICES
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on November 2, 2021,
Johnson Matthey, Inc., 2003 Nolte Drive
West Deptford, New Jersey 08066–1742,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
20:22 Jan 10, 2022
Jkt 256001
Drug
Code
Controlled Substance
Schedule
Gamma Hydroxybutyric Acid ..
Marihuana ...............................
Tetrahydrocannabinols ...........
Noroxymorphone ....................
Difenoxin .................................
Amphetamine ..........................
Methamphetamine ..................
Lisdexamfetamine ...................
Methylphenidate ......................
Nabilone ..................................
4-Anilino-N-Phenethyl-4-Piperidine (ANPP).
Norfentanyl ..............................
Cocaine ...................................
Codeine ...................................
Dihydrocodeine .......................
Oxycodone ..............................
Hydromorphone ......................
Diphenoxylate .........................
Ecgonine .................................
Hydrocodone ...........................
Levorphanol ............................
Meperidine ..............................
Methadone ..............................
Methadone intermediate .........
Morphine .................................
Thebaine .................................
Opium tincture ........................
Oxymorphone .........................
Noroxymorphone ....................
Alfentanil .................................
Remifentanil ............................
Sufentanil ................................
Tapentadol ..............................
Fentanyl ..................................
Schedule
2010
7360
7370
9145
9168
1100
1105
1205
1724
7379
8333
I
I
I
I
I
II
II
II
II
II
II
8366
9041
9050
9120
9143
9150
9170
9180
9193
9220
9230
9250
9254
9300
9333
9630
9652
9668
9737
9739
9740
9780
9801
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to bulk
manufacture the listed controlled
substances for the internal use
intermediates or for sale to its
customers. In reference to drug codes
7360 (Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. The company plans to bulk
manufacture for either internal usage as
intermediates or to sale to customers as
Active Pharmaceutical Ingredients
(API). No other activities for these drug
codes are authorized for this
registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2022–00326 Filed 1–10–22; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–944]
Importer of Controlled Substances
Application: Nexus Pharmaceuticals,
Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before February 10, 2022. Such
persons may also file a written request
for a hearing on the application on or
before February 10, 2022.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on October 25, 2021,
Nexus Pharmaceuticals, Inc., 10300
128th Avenue, Pleasant Prairie,
Wisconsin 53158–7338, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Controlled
substance
Remifentanil ......
Drug code
9739
Schedule
I
The company plans to import the
listed controlled substance for research
and analytical testing purposes.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale. No other activity for
this drug code is authorized for this
registration.
Brian S. Besser,
Acting Assistant Administrator.
Nexus Pharmaceuticals, Inc.
has applied to be registered as an
SUMMARY:
importer of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
[FR Doc. 2022–00329 Filed 1–10–22; 8:45 am]
BILLING CODE P
E:\FR\FM\11JAN1.SGM
11JAN1
]]>Agencies
[Federal Register Volume 87, Number 7 (Tuesday, January 11, 2022)]
[Notices]
[Page 1435]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00329]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-944]
Importer of Controlled Substances Application: Nexus
Pharmaceuticals, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Nexus Pharmaceuticals, Inc. has applied to be registered as an
importer of basic class(es) of controlled substance(s). Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before February 10,
2022. Such persons may also file a written request for a hearing on the
application on or before February 10, 2022.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on October 25, 2021, Nexus Pharmaceuticals, Inc., 10300
128th Avenue, Pleasant Prairie, Wisconsin 53158-7338, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Remifentanil....................... 9739 I
------------------------------------------------------------------------
The company plans to import the listed controlled substance for
research and analytical testing purposes. Approval of permit
applications will occur only when the registrant's business activity is
consistent with what is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the import of Food and Drug
Administration-approved or non-approved finished dosage forms for
commercial sale. No other activity for this drug code is authorized for
this registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2022-00329 Filed 1-10-22; 8:45 am]
BILLING CODE P
